![]()

![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()

Lucid Group, the award-winning global medical communications
company with offices in London, Buckinghamshire, Macclesfield and New York, has
announced the launch of a new agency specialising in rare and specialist
diseases.
Vivid MedComms Limited, based in Loudwater Buckinghamshire,
will be headed by Alison Cantle (Managing Director), who has over 20 years’
medical communications experience.
This move mirrors an industry-wide shift towards focusing on
rare and specialist diseases, with revenues from orphan drugs outpacing sales
of mainstream drugs for the last decade, a trend that’s expected to continue
for the next 30 years. According to the Orphan Drug Report (2015), sales of
orphan drugs will account for 20% of all prescription drug sales by 2020.
Alison commented, “Our business in rare diseases has
increased threefold over the last year. Making the decision to create a new
stand-alone company focused on this area is an obvious choice. We have
developed a dedicated and talented team of account handlers and medical writers
brimming with specific skills and experience related to developing excellent
comms programmes in rare diseases. The team are excited by the challenge and
looking forward to transforming the lives of both clients and teams in this
space.”
If you would like to discuss medical education support from
the Vivid team, please contact:
E: Alison@lucid-uk.com
M: 07780 455605